The combination therapy of Q-K treats NSCLC I/II clinical effects is encouraging and phase III clinical practice is planned

The above-mentioned Q-K treatment is the first, non-blind, multi-arm Phase I/II clinical trial, which mainly evaluates the safety and toerability of Quavonlimab combined K drugs for first-line treatment of patients with advanced NSCLC, followed by ORR, PFS, Total Lifetime (OS) and DOR.
in a 16.9-month mid-level follow-up period (with a time range of 7-21.3 months), the results showed the effectiveness of Q-K combination therapy at the primary and secondary endpoints of clinical trials such as ORR/PFS/OS.
and ability data presented in the test supported the recommended dose of Q drug 25mg Q6W-K as an extended group.
safety, 85% of patients had treatment-related adverse events (TRAEs), and 36% of all treatment groups had TRAEs of level 3 and above.
addition, OrR was 40.0% (95%CI, 24.9-56.7) and 37.5% (95% CI, 22.7-) in NSCLC patients. 54.2), 27.5 per cent (95 per cent CI, 14.6-43.9) and 35.7 per cent (95 per cent CI, 12.8-64.9).
the results showed that the Q-K combination therapy had good safety and effectiveness, was free of unintended toxicity, and showed encouraging anti-tumor activity. Dr Vicki Goodman, Vice President of Oncology Clinical Research at
Merck Research Laboratory, said: "The latest data from our anti-CTLA-4 antibody Quavonlimab in combination with KEYTRUDA support the ongoing development of this new combination, and a Phase III clinical study using Quavonlimab in combination with KEYTRUDA to treat advanced non-small cell lung cancer is already planned.
" Reference Merck Presents Three-Year Survival Data for KEYTRUDA (pembrolizumab) in With And Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308)